Search results for "BODIES"

showing 10 items of 2217 documents

Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci

2006

No vaccine is available for preventing infections by serogroup B Neisseria meningitidis (MenB), which accounts for a major portion of meningococcal cases in developed countries, because of the poor immunogenicity of the capsular polysaccharide (CP) even after protein conjugation. We have previously induced anticapsular antibodies by immunization with a single chain variable fragment (scFv), which mimics a protective CP epitope. This surrogate antigen, however, was ineffective at inducing serum bactericidal activity, an accepted marker of protection in humans. Serum bactericidal activity was consistently achieved by immunizing mice with the scFv-encoding gene. Immunization with vectors witho…

Blood Bactericidal ActivityImmunologyImmunoglobulin Variable Regionchemical and pharmacologic phenomenaBlood Bactericidal ActivityNeisseria meningitidis Serogroup BEpitopeArticleMicrobiologyDNA vaccinationMiceAntigenserogroup B Neisseria meningitidis; single chain variable fragment; DNA vaccinationChlorocebus aethiopsVaccines DNAImmunology and AllergyAnimalsRats WistarMice Inbred BALB CbiologyImmunogenicityArticlesVirologyAntibodies BacterialRatsBacterial vaccineMeningococcal InfectionsImmunizationAnimals NewbornBacterial VaccinesCOS Cellsbiology.proteinAntibody
researchProduct

Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals

1991

SUMMARYTwo sensitive sandwich ELISAs based on monoclonal antibodies directed to native C6 and C7 allowed the detection and quantitation of these complement proteins in 20 out of 37 serum samples from individuals who had previously been classified as deficient in these proteins as assessed by immunochemical and/or functional assays. Furthermore, serum from four C6-deficient and one combined C6-/C7-deficient individual showed an increase in the terminal complement complex (TCC) and a decrease in native C6 and C7 after complement activation as assayed by specific ELISAs. Despite their (incomplete) deficiencies, these individuals therefore possess functionally active terminal complement protein…

Blood Bactericidal Activitymedicine.drug_classImmunoblottingImmunologyEnzyme-Linked Immunosorbent AssayBiologyMonoclonal antibodyComplement Hemolytic Activity AssaySpecimen Handling03 medical and health sciences0302 clinical medicineTerminal complement complexImmunopathologymedicineHumansImmunology and AllergyComplement ActivationVolume concentration030304 developmental biology0303 health sciencesTemperatureZymosanAntibodies MonoclonalComplement deficiencyComplement C9Serum samplesmedicine.diseaseMolecular biologyComplement C7Complement C63. Good healthComplement (complexity)Complement systemImmunologyElectrophoresis Polyacrylamide GelResearch Article030215 immunologyClinical and Experimental Immunology
researchProduct

Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection.

2011

BACKGROUND AND AIMS: Steatosis and insulin resistance (IR) are the major disease modifying in patients with chronic hepatitis C (CHC). Only few studies evaluated these features in patients with chronic hepatitis B (CHB). We aimed to assess the prevalence and the factors related to steatosis and IR in CHB patients, compared with CHC subjects, and to evaluate the potential association between these features and fibrosis severity. MATERIAL AND METHODS: One hundred and seventy consecutive patients with CHB (28 HBeAg positive, 142 HBeAg negative), were evaluated using liver biopsy and metabolic measurements and matched for sex, age and body mass index with 170 genotype 1 CHC patients. IR was def…

Blood GlucoseLiver CirrhosisMaleSettore MED/09 - Medicina InternaBiopsyEnzyme-Linked Immunosorbent AssaySettore MED/08 - Anatomia PatologicaSettore MED/13 - EndocrinologiaBody Mass IndexteatosisHBVPrevalenceHumansInsulinHepatitis B AntibodiesTriglyceridesImmunoassaySettore MED/12 - GastroenterologiaHBV;HCV;steatosisAlanine TransaminaseHepatitis BHepatitis CFatty LiverItalyHCVRegression AnalysisFemaleInsulin ResistanceLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Evidence for hypothalamic ketone bodies sensing: impact on food intake and peripheral metabolic responses in mice

2016

Monocarboxylates have been implicated in the control of energy homeostasis. Among them, the putative role of ketone bodies produced notably during high-fat diet (HFD) has not been thoroughly explored. In this study, we aimed to determine the impact of a specific rise in cerebral ketone bodies on food intake and energy homeostasis regulation. A carotid infusion of ketone bodies was performed on mice to stimulate sensitive brain areas for 6 or 12 h. At each time point, food intake and different markers of energy homeostasis were analyzed to reveal the consequences of cerebral increase in ketone body level detection. First, an increase in food intake appeared over a 12-h period of brain keton…

Blood GlucoseMale0301 basic medicineobesitynervous-systemPhysiology[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionEndocrinology Diabetes and MetabolismKetone BodiesEnergy homeostasisEatingMicebodiesHomeostasisGlucose homeostasisoxidative stressAgouti-Related ProteinNeuropeptide YPhosphorylationmonocarboxylate transporters2. Zero hunger[ SDV.MHEP.PHY ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]fat massHypothalamusKetone bodiesStarvation responseketogenic mediterranean dietweight-lossmedicine.medical_specialtybeta-hydroxybutyrateHypothalamusBiologyDiet High-Fat03 medical and health sciencesInsulin resistancerat-brainPhysiology (medical)Internal medicinemedicine[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]Animalsglucose homeostasisAdenylate Kinase/metabolism; Agouti-Related Protein/metabolism; Animals; Blood Glucose; Diet High-Fat; Eating/drug effects; Eating/physiology; Energy Metabolism/drug effects; Energy Metabolism/physiology; Gluconeogenesis/drug effects; Gluconeogenesis/physiology; Homeostasis; Hypothalamus/drug effects; Hypothalamus/metabolism; Insulin Resistance/physiology; Ketone Bodies/pharmacology; Male; Mice; Mice Inbred C57BL; Neuropeptide Y/metabolism; Phosphorylation/drug effectsenergy homeostasisAdenylate KinaseGluconeogenesismedicine.diseaseMice Inbred C57BL030104 developmental biologyEndocrinologyGluconeogenesislow-carbohydrateInsulin ResistanceEnergy Metabolism[SDV.AEN]Life Sciences [q-bio]/Food and NutritionHomeostasis
researchProduct

Protective action of 1,3-butanediol in cerebral ischemia. A neurologic, histologic, and metabolic study.

1987

1,3-Butanediol (BD) is converted in the body to β-hydroxybutyrate, and previous studies have shown that hyperketonemia had beneficial effects in experimental models of generalized hypoxia. The aim of this study was to determine if BD would reduce brain damage following cerebral ischemia. A transient forebrain ischemia of 30-min duration was induced by the four-vessel occlusion technique in control and BD-treated rats (25 mmol/kg, i.p.; 30 min prior to ischemia). BD treatment led to significant improvement of neurologic deficit during the 72-h recovery period and reduced neuronal damage in the striatum and cortex but not in the CA1 sector of the hippocampus. Evaluation of cerebral energy me…

Blood GlucoseMalemedicine.medical_specialtyIschemiaHydroxybutyratesBlood PressureBrain damageHippocampusPhosphocreatinechemistry.chemical_compoundInternal medicinemedicine13-ButanediolAnimalsEnergy chargeButylene GlycolsCerebral CortexNeurons3-Hydroxybutyric Acidbusiness.industryBrainHypoxia (medical)medicine.diseaseCorpus StriatumRatsEndocrinologyNeurologychemistryIschemic Attack TransientLactic acidosisKetone bodiesNeurology (clinical)medicine.symptomCardiology and Cardiovascular MedicinebusinessEnergy MetabolismJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
researchProduct

Fasting prior to transient cerebral ischemia reduces delayed neuronal necrosis.

1990

A transient brain ischemia of 30-min duration was induced by the four-vessel occlusion technique in normally fed and in 48-hr-fasted rats. Evaluation of brain damage 72 hr after ischemia showed that fasting reduced neuronal necrosis in the striatum, the neocortex, and the lateral part of the CA1 sector of hippocampus. Signs of status spongiosis in the pars reticulata of the substantia nigra were seen in 75% of fed rats and in only 19% of fasted rats. The protective effect was associated with reduction in mortality and in postischemic seizure incidence. The metabolic changes induced by fasting were evaluated before and during ischemia. After 30 min of four-vessel occlusion, fasted rats showe…

Blood GlucoseMalemedicine.medical_specialtyIschemiaHydroxybutyratesSubstantia nigraBlood PressureBrain damageBiochemistryBrain ischemiaCellular and Molecular Neurosciencechemistry.chemical_compoundNecrosisReference ValuesInternal medicinemedicineAnimalsNeuronsGlycogen3-Hydroxybutyric Acidbusiness.industryAdenine NucleotidesBrainRats Inbred StrainsFastingmedicine.diseaseRatsEndocrinologyGlucosechemistryIschemic Attack TransientOrgan SpecificityLactic acidosisAnesthesiaKetone bodiesLactatesNeurology (clinical)medicine.symptomPars reticulatabusinessEnergy MetabolismMetabolic brain disease
researchProduct

Autoimmune Diabetes Induced by the β-cell Toxin STZ: Immunity to the 60-kDa Heat Shock Protein and to Insulin

1994

Administered at a suitably low dose, the toxin streptozotocin (STZ) can trigger an autoimmune process leading to destruction of the beta-cells of the pancreatic islets. In this study, we examined specific immunological reactions in mice before and during the development of STZ-induced autoimmune diabetes. We now report that the development of spontaneous autoantibodies to insulin can serve as a marker of susceptibility to a low dose of STZ. Susceptible male mice of the C57BL/KsJ strain manifested such anti-insulin antibodies, and resistant female mice did not. Administration of a low dose of STZ (five daily doses each of 30 mg/kg) induced transient hyperglycemia approximately 20-30 days lat…

Blood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentBiologyActive immunizationmedicine.disease_causeStreptozocinAutoimmune DiseasesDiabetes Mellitus ExperimentalAutoimmunityMiceInternal medicineDiabetes mellitusInternal MedicinemedicineAnimalsInsulinHeat-Shock ProteinsAutoantibodiesAutoimmune diseaseMice Inbred BALB CPancreatic isletsInsulinnutritional and metabolic diseasesmedicine.diseaseStreptozotocinMice Inbred C57BLEndocrinologymedicine.anatomical_structureFemaleImmunizationBeta cellmedicine.drugDiabetes
researchProduct

Correction of glycaemia and GLUT1 level by mildronate in rat streptozotocin diabetes mellitus model

2011

Anti-ischaemic drug mildronate suppresses fatty acid metabolism and increases glucose utilization in myocardium. It was proposed that it could produce a favourable effect on metabolic parameters and glucose transport in diabetic animals. Rats with streptozotocin diabetes mellitus were treated with mildronate (100 mg/kg daily, per os, 6 weeks). Therapeutic effect of mildronate was monitored by measuring animal weight, concentrations of blood glucose, insulin, blood triglycerides, free fatty acids, blood ketone bodies and cholesterol, glycated haemoglobin per cent (HbA1c%) and glucose tolerance. GLUT1 mRNA and protein expression in kidneys, heart, liver and muscles were studied by means of re…

Blood Glucosemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentClinical BiochemistryBiochemistryStreptozocinDiabetes Mellitus Experimentalchemistry.chemical_compoundInternal medicineDiabetes mellitusDiabetes MellitusmedicineAnimalsBody SizeHypoglycemic AgentsInsulinRNA MessengerRats WistarTriglyceridesGlycated HemoglobinGlucose Transporter Type 1Glucose tolerance testmedicine.diagnostic_testFatty acid metabolismbiologyCholesterolbusiness.industryInsulinFatty AcidsGlucose transporternutritional and metabolic diseasesCell BiologyGeneral MedicineGlucose Tolerance Testmedicine.diseaseRatsEndocrinologychemistrybiology.proteinKetone bodiesGLUT1businessMethylhydrazinesCell Biochemistry and Function
researchProduct

Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.

2006

Platelet activation causes conformational changes of integrin GPIIb/IIIa (α IIb β 3 ), resulting in the exposure of its ligand-binding pocket. This provides the unique possibility to design agents that specifically block activated platelets only. We used phage display of single-chain antibody (scFv) libraries in combination with several rounds of depletion/selection to obtain human scFvs that bind specifically to the activated conformation of GPIIb/IIIa. Functional evaluation of these scFv clones revealed that fibrinogen binding to human platelets and platelet aggregation can be effectively inhibited by activation-specific scFvs. In contrast to clinically used GPIIb/IIIa blockers, which ar…

Blood PlateletsCarotid Artery DiseasesBleeding TimePhysiologyAmino Acid MotifsMolecular ConformationEptifibatidePlatelet Glycoprotein GPIIb-IIIa ComplexFerric CompoundsAntibodiesMiceChloridesFibrinolytic AgentsmedicineAbciximabAnimalsHumansPlateletPlatelet activationChemistryFibrinogen bindingFibrinogenThrombosisTirofibanPlatelet ActivationMolecular biologyComplementarity Determining RegionsMice Inbred C57BLTirofibanImmunologyEptifibatidePlatelet aggregation inhibitorTyrosineCardiology and Cardiovascular MedicineGlycoprotein IIb/IIIaPeptidesPlatelet Aggregation Inhibitorsmedicine.drugCirculation research
researchProduct

Haemostasis in chronic kidney disease

2013

The coagulation system has gained much interest again as new anticoagulatory substances have been introduced into clinical practice. Especially patients with renal failure are likely candidates for such a therapy as they often experience significant comorbidity including cardiovascular diseases that require anticoagulation. Patients with renal failure on new anticoagulants have experienced excessive bleeding which can be related to a changed pharmacokinetic profile of the compounds. However, the coagulation system itself, even without any interference with coagulation modifying drugs, is already profoundly changed during renal failure. Coagulation disorders with either episodes of severe bl…

Blood PlateletsExcessive Bleedingmedicine.medical_specialtymedicine.medical_treatmentHemorrhageThrombophiliaInternal medicinemedicineHumansRenal InsufficiencyRenal Insufficiency ChronicHemostatic functionBlood CoagulationCoagulation DisorderHemostasisTransplantationbusiness.industryAnticoagulantsThrombosisBlood Coagulation Disordersmedicine.diseaseThrombosisSurgeryOxidative StressCoagulationNephrologyAntibodies AntiphospholipidCardiologyEndothelium VascularHemodialysisbusinessKidney diseaseNephrology Dialysis Transplantation
researchProduct